Regional Regulatory Lineage
PREVAIL Ebola Trials, AVAREF Harmonization & Historical Statutes
Documenting how West African epidemic response shaped modern multi-country ethics review, joint regulatory timelines, and community engagement.
The Partnership for Research on Ebola Virus in Liberia (PREVAIL) established that Phase II/III randomized clinical trials can maintain full ICH-GCP compliance, independent REC oversight, and community-informed consent even under acute epidemic conditions—laying operational groundwork for AVAREF joint multi-country reviews across Africa.
Primary reference: NIAID PREVAIL Partnership & WHO AVAREF.
AVAREF Joint Review Harmonization
The African Vaccine Regulatory Forum (AVAREF), convened by WHO AFRO, aligns National Regulatory Authorities (NRAs) and National Ethics Committees (RECs) through standardized submission templates and joint dossier evaluations. During public health emergencies, AVAREF joint reviews target a 10-to-15-day decision window across participating member states while preserving sovereign national sign-off.
Liberia Health Research Regulatory Continuity
Within Liberia's clinical research ecosystem, ethical review by the NREB operates alongside product-level regulatory authorization from the Liberia Medicines and Health Products Regulatory Authority (LMHRA). Researchers seeking current statutory filing portals should consult the official NIH ClinRegs Liberia Directory.
| Era / Milestone | Operational Body | Lasting Governance Contribution |
|---|---|---|
| 2006-2013 | AVAREF Founding Cohort | Standardized African NRA + REC joint clinical trial review procedures |
| 2014-2016 | PREVAIL I-III & NREB-LR | Demonstrated randomized placebo/vaccine trial ethics during active Ebola outbreak |
| 2018-2025 | NREB-LR & LMHRA Dual Track | Codified 21-member quorum, MTA export rules, and ClinRegs LBR-18 indexing |